Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal is divided into three parts. Human Gene Therapy, the flagship published 12 times per year, HGT Methods, a bimonthly journal, focused on the applications of gene therapy to product testing and development, and HGT Clinical Development, a quarterly journal, publishing data relevant to the regulatory review and commercial development of cell and gene therapy products. This unique three part program provides 22 issues of essential research, technologies, translation, and applications to promote the development of gene therapy products into effective therapeutics for treating human disease—and move this revolutionary field forward.

The Journal is led by a world-renowned Editorial Board with Editor-in-Chief Terence R. Flotte, MD, at the helm; Deputy Editor Europe Thierry VandenDriessche, PhD; Deputy Editor U.S. Barry J. Byrne, MD, PhD; Human Gene Therapy Editor Guangping Gao, PhD; Methods Editor Hildegard Büning, PhD; and Clinical Development Editor James M. Wilson, MD, PhD.

Human Gene Therapy is the Official Journal of 9 international societies, including ESGCT.

ESGCT members can access the Journal via the member website, and we encourage members to recommend the expanded Human Gene Therapy program to their library or institution to facilitate collaboration with colleagues. In addition, all ESGCT members are given the option to receive Genetic Engineering & Biotechnology News on a complimentary basis by filling out a simple qualification form.

The Journal welcomes your manuscript submissions. All accepted papers are published online ahead of print. Read a free issue of Human Gene Therapy online.

Latest Impact Factor: 3.755
2014 Journal Citation Reports® published by Thomson Reuters, 2015